Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Therapy Areas

Cardiovascular

Set Alert for Cardiovascular

Latest From Cardiovascular

Gemphire Reels From Two R&D Blows

A series of setbacks for gemcabene has left the Livonia, MI-based company reeling, but management remains committed to its lead product.

Clinical Trials Research & Development

Portola's Rocky Commercial Transition On Show In Q2, With No CEO

Company reported only $33,000 in sales for late anticoagulant market entrant Bevyxxa and $2.2m for the antidote Andexxa, leaving a lot of challenges ahead after the retirement of CEO Bill Lis, effective Aug. 1.

Sales & Earnings Launches

Cosentyx Carries Novartis Sales But Kymriah Manufacturing Gives Cause For Concern

The Swiss major is very happy indeed with the growth trajectory of Cosentyx and Entresto and pleased with how its migraine drug Aimovig has started. However the revelation of manufacturing problems with its CAR-T therapy Kymriah marred Novartis' second-quarter results.

Sales & Earnings Manufacturing

14 Approvals To Look Out For In Q3

As many as 14 new products are up for US approval in the third quarter, research by Informa Pharma's Biomedtracker shows. Scrip takes a look at the candidates and their chances of reaching the market.

Approvals Policy & Regulation

Drayson Outlines Ambition To Build Clinician-Driven AI Business Using NHS Data

Former UK science minister Lord Drayson explains to Scrip his plans for Sensyne Health, an Oxford, UK-based AI-focused healthcare technology company, to go public after securing a second deal with an NHS Foundation Trust while seeking big pharma research collaborations.

Artificial Intelligence Clinical Trials

Novo Nordisk Seen Readying Steps To Offset US Pressures, Including Job Cuts

Novo Nordisk is rumored to be considering laying off up to 3,000 staff and dropping its long-term financial targets due to challenging US market conditions which the group flagged in its first-quarter update in May.

Business Strategies Companies
See All

CNS

Set Alert for CNS

Latest From Neurology

Mavenclad Is Merck KGaA Bright Spot As Q2 Sales Slip

With strong quarterly sales of Mavenclad in Europe, and a recent re-filing of the drug with the FDA, Merck KGaA continues to play the waiting game for top-line growth to return as it banks on the new addition to its MS franchise.

Companies Sales & Earnings

Generic Blow Looms For Lundbeck

With a new CEO taking the reins in September and a candidate entering the clinic for Parkinson’s disease, Lundbeck has opportunities for refreshment, both in the pipeline and the boardroom. But with generic competition battering down the company’s financial outlook, it may not be enough to bring the market along for the ride.

Sales & Earnings Commercial

Lundbeck Breaks Into MAb Development, Adds To Suite Of Parkinson's Candidates

Denmark's mid-sized biopharma, Lundbeck, has taken another potential Parkinson's disease therapeutic into early clinical studies, the third this year, and this time it's a monoclonal antibody, not a small molecule.

 

Neurology Research & Development

Global First As Japan Starts iPS Cell Trial In Parkinson's

Building on its national expertise in the area, Japan is starting the first clinical trial globally to assess the use of iPS-derived cells for the treatment of Parkinson’s disease.

Japan Clinical Trials

Laquinimod Disappoints Again, This Time In Huntington's Disease

Laquinimod fails to impress in a Phase II study in Huntington's disease, adding to a series of clinical trial setbacks over past years for the potential oral immunomodulator.

 

Clinical Trials Neurology

UCB Looks To Its Next Wave Of Innovative Products

Early clinical-stage products for neurological and autoimmune diseases are progressing through the European biopharma's pipeline.

Immune Disorders Neurology
See All

Immunology

Set Alert for Immunology

Latest From Immune Disorders

Orchard Raises Another $150m For Gene Therapy Pot

Having recently got hold of GlaxoSmithKline's gene therapy assets, Orchard has completed another whopping financing which has got observers thinking that an IPO could soon be in the offing.

Financing Rare Diseases

UCB Looks To Its Next Wave Of Innovative Products

Early clinical-stage products for neurological and autoimmune diseases are progressing through the European biopharma's pipeline.

Immune Disorders Neurology

Roche Says New Drugs Can Allow Safe Navigation Despite Biosimilar Threats

Swiss group raises guidance for second time this year despite looming biosimilar competition and Cabilly patent loss.

Business Strategies Biosimilars

For GSK R&D Head Hal Barron 'There's No Place Like Home' For Seeding Innovation

GSK President R&D Hal Barron came to a big investor meeting with one bit of tangible news, a collaboration with consumer genetics leader 23andMe. Barron and CEO Emma Walmsley talked about the deal and Barron's California headquarters in a media briefing. 

Artificial Intelligence Business Strategies

Sangamo Buys TxCell To Get In Early on CAR-Tregs In Immunology

Sangamo is to pay €72m to acquire France's TxCell, a specialist in chimeric antigen receptor-modified regulatory T-cells. It hopes ultimately to apply its zinc finger nuclease gene editing technology to develop next-generation allogeneic CAR-Treg therapies for immunological conditions.

M & A Platform Technologies

Strong Sobi With New Asset: A Takeover Target For Sanofi?

Swedish rare diseases specialist Sobi has reported strong financials and the acquisition of a rare disease candidate on the verge of US approval. Could partner Sanofi pop the question soon?

Deals M & A
See All
Advertisement

Infectious

Set Alert for Infectious Diseases

Latest From Infectious Diseases

Insmed’s Amikacin Moves Closer To US Market In Refractory Lung Disease

FDA panel's recommendation that liposome inhalation suspension be labeled only for refractory nontuberculous mycobacterial lung disease and not first-line use aligns with analyst expectations; panel cites lack of clinical studies in treatment-naive patients and adverse event profile as reasons for limiting drug to patients with limited or no treatment options.


Infectious Diseases Respiratory

Evotec Sets Empire Building Sights On Infectious Disease Space

As others shun anti-infectives, Evotec is consolidating its position. Through an alliance with Sanofi it is evaluating new anti-infectives in three areas, and expects soon to advance its first candidate therapeutic into the clinic.

 

Infectious Diseases Clinical Trials

RedHill's Antibiotic Approach For Crohn's Shows Promise, Caveats Remain

Top-line data for a Phase III trial of RedHill's antibiotic combination for use in Crohn's disease show the study has hit its primary endpoint, but there is still some way to go before filings can be made for the novel approach.

Clinical Trials Research & Development

Podcast: Tackling The AMR Crisis

Infectious Diseases

AbbVie HCV Revenue Surprises Again, But Falloff Is Coming

Led by eight-week, pan-genotypic combo Mavyret, AbbVie’s HCV franchise grows despite a declining US market that has taken a toll on competitors Gilead and Merck. Still, AbbVie expects a falloff in the third quarter.

Sales & Earnings Commercial

For GSK R&D Head Hal Barron 'There's No Place Like Home' For Seeding Innovation

GSK President R&D Hal Barron came to a big investor meeting with one bit of tangible news, a collaboration with consumer genetics leader 23andMe. Barron and CEO Emma Walmsley talked about the deal and Barron's California headquarters in a media briefing. 

Artificial Intelligence Business Strategies
See All

Metabolic

Set Alert for Metabolic

Latest From Metabolic Disorders

With Novo Nordisk Dependent On GLP-1s, Even Perceived Price Pressures Can Hurt

Long-term top-line market forecasts for Novo Nordisk are heavily reliant on its GLP-1 portfolio's potential - so pricing uncertainties, especially in the US,  can unnerve sentiment, as seen when it reported Q2 results.

Commercial Companies

PCSK9 Pick-Me-Up: New Cholesterol Guidelines May Mean Lower LDL Targets

Sales of PCSK9 inhibitors have been improving, though are still low, and inclusion of lower LDL-C targets in practice guidelines coming this November would be a boost.

Clinical Trials Research & Development

Lysosomal Storage Disorders: Azafaros Takes Aim At Small Molecules

BioGeneration Ventures has given birth to a new European biotech, Azafaros, supplying seed funding for the development of a new generation of compounds to tackle rare metabolic disorders.

 

Financing Rare Diseases

Cosentyx Carries Novartis Sales But Kymriah Manufacturing Gives Cause For Concern

The Swiss major is very happy indeed with the growth trajectory of Cosentyx and Entresto and pleased with how its migraine drug Aimovig has started. However the revelation of manufacturing problems with its CAR-T therapy Kymriah marred Novartis' second-quarter results.

Sales & Earnings Manufacturing

Norgine Holds Out Cetilistat Hope As Takeda Alliance Ends In Challenging Japan Market

Takeda and Norgine’s decision to finally end their alliance for cetilistat in Japan, years after the obesity drug was approved in its first potential market, serves as another sign of the sector’s challenges in the country.

Japan Commercial

Eisai's Obesity Drug Belviq Passes Cardiovascular Outcomes Test

The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.

Clinical Trials FDA
See All

Oncology

Set Alert for Oncology

Latest From Cancer

Artios Pharma Hooks Novartis & Pfizer In Over-Subscribed £65M Series B Round

With DNA damage repair pathways attracting a lot of attention as potential targets against various cancers, three-year old Artios Pharma has raised £65 million in an over-subscribed Series B round to fund the clinical development of its pipeline through to 2023.
Financing Cancer

Mavenclad Is Merck KGaA Bright Spot As Q2 Sales Slip

With strong quarterly sales of Mavenclad in Europe, and a recent re-filing of the drug with the FDA, Merck KGaA continues to play the waiting game for top-line growth to return as it banks on the new addition to its MS franchise.

Companies Sales & Earnings

Regeneron And Bluebird Team Up In Cell Therapy "Joint Venture"-Style Deal

Regeneron will make a $100m equity investment in bluebird to collaborate on the discovery of antibodies and T cell receptors, with the hope of building out in immuno-oncology and overcoming some of the early cell therapy challenges. Regeneron's business development chief talks to Scrip about its strategy.

Deals ImmunoOncology

Tazemetostat Setbacks Hit Epizyme

As drug fails in DLBCL, firm focuses on lifting partial clinical hold on other trials. A first filing in a rare sarcoma has also been pushed back.

Clinical Trials Research & Development

China Appetite For HPV Vaccine Delivers Surprise For Merck

When Merck realized that demand in China is so large for its HPV vaccine Gardasil, the US company wanted to understand more about the market, but a coordinated pre-launch awareness campaign appears to have helped. 

China Vaccines

Otsuka's Guadecitabine Fails in ASTRAL-1 But AML Studies Continue

Otsuka's guadecitabine has missed co-primary endpoints in older treatment-naïve AML patients but it continues to be evaluated in relapsed and refractory patients, in a therapeutic area undergoing considerable innovation.

 

Clinical Trials Cancer
See All

Respiratory

Set Alert for Respiratory

Latest From Respiratory

Bayer Targets COPD In Haplogen Antiviral Pact

Respiratory viral infections are a frequent cause of COPD exacerbations and the German major is joining forces with the Austrian biotech and Evotec to find new antivirals to tackle the disease.

Deals Respiratory

Insmed’s Amikacin Moves Closer To US Market In Refractory Lung Disease

FDA panel's recommendation that liposome inhalation suspension be labeled only for refractory nontuberculous mycobacterial lung disease and not first-line use aligns with analyst expectations; panel cites lack of clinical studies in treatment-naive patients and adverse event profile as reasons for limiting drug to patients with limited or no treatment options.


Infectious Diseases Respiratory

Timing Is Everything As Mereo Still Eyes US Listing

The London-headquartered firm believes that its efficient control of costs and strong data in support of its investigational treatments for rare respiratory, bone and endocrine diseases will attract investors across the Atlantic once it decides to refile for a listing on the Nasdaq.

Strategy Financing

Nucala Among Flurry Of New Respiratory Products On Indian Horizon

Novel asthma/COPD drugs, including GlaxoSmithKline’s biologic therapy Nucala, are on the horizon in India, set to expand treatment options in the competitive segment. But pricing is expected to be key in pushing uptake, and health care delivery in asthma/COPD in India remains rather sub-optimal, notwithstanding the interest around new launches.

Commercial Strategy

Boehringer Takes Out Option For Cystic Fibrosis Gene Therapy

The German major is making its first foray into gene therapy and is looking to license a new viral vector-based product that could create a new therapeutic pathway for CF patients, regardless of their mutations.

Rare Diseases Respiratory

Flush With Fresh Funds, ReViral CEO Outlines RSV Trial Plans

Biotech's CEO says its lead respiratory candidate RV521 has 'caught up with rivals' in efficacy and safety.

Financing Respiratory
See All
Advertisement
UsernamePublicRestriction

Register